Catalent Inc logo

CTLT - Catalent Inc Share Price

$110.6 -0.4  -0.4%

Last Trade - 16/04/21

Large Cap
Market Cap £13.70bn
Enterprise Value £15.32bn
Revenue £2.51bn
Position in Universe 610th / 6851
Unlock CTLT Revenue
Relative Strength (%)
1m +3.30%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -13.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1,831 1,848 2,075 2,463 2,518 3,094 3,888 4,267 +11.1%
+367.2 -53.8 +5.3 +13.0 +0.7 +12.3 +117.8 +15.5
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, CatalentInc revenues increased 27% to $1.76B. Net income applicableto common stockholders increased from $26.9M to $145.4M.Revenues reflect Biologics segment increase of 89% to $781M, Oral and Specialty Delivery segment increase of 19% to$328.2M, United States segment increase of 35% to $1.05B,Europe segment increase of 41% to $607.8M. Net incomebenefited from Other increase from $3.2M to $18.7M
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CTLT Revenue Unlock CTLT Revenue

Net Income

CTLT Net Income Unlock CTLT Revenue

Normalised EPS

CTLT Normalised EPS Unlock CTLT Revenue

PE Ratio Range

CTLT PE Ratio Range Unlock CTLT Revenue

Dividend Yield Range

CTLT Dividend Yield Range Unlock CTLT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CTLT EPS Forecasts Unlock CTLT Revenue
Profile Summary

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated March 14, 2007
Public Since July 31, 2014
No. of Shareholders: 14
No. of Employees: 13,900
Sector Healthcare
Industry Pharmaceuticals
Exchange New York Stock Exchange
Shares in Issue 170,226,514
Free Float (0.0%)
Eligible for
CTLT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CTLT
Upcoming Events for CTLT
Monday 3rd May, 2021 Estimate
Q3 2021 Catalent Inc Earnings Release
Monday 30th August, 2021 Estimate
Q4 2021 Catalent Inc Earnings Release
Frequently Asked Questions for Catalent Inc
What is the Catalent Inc share price?

As of 16/04/21, shares in Catalent Inc are trading at $110.6, giving the company a market capitalisation of £13.70bn. This share price information is delayed by 15 minutes.

How has the Catalent Inc share price performed this year?

Shares in Catalent Inc are currently trading at $110.6 and the price has moved by 0.101k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Catalent Inc price has moved by 36.42% over the past year.

What are the analyst and broker recommendations for Catalent Inc?

Of the analysts with advisory recommendations for Catalent Inc, there are there are currently 6 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Catalent Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Catalent Inc next release its financial results?

Catalent Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Catalent Inc dividend yield?

Catalent Inc does not currently pay a dividend.

Does Catalent Inc pay a dividend?

Catalent Inc does not currently pay a dividend.

When does Catalent Inc next pay dividends?

Catalent Inc does not currently pay a dividend.

How do I buy Catalent Inc shares?

To buy shares in Catalent Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Catalent Inc?

Shares in Catalent Inc are currently trading at $110.6, giving the company a market capitalisation of £13.70bn.

Where are Catalent Inc shares listed? Where are Catalent Inc shares listed?

Here are the trading details for Catalent Inc:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: CTLT
What kind of share is Catalent Inc?

Based on an overall assessment of its quality, value and momentum, Catalent Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Catalent Inc share price forecast 2021?

Shares in Catalent Inc are currently priced at $110.6. At that level they are trading at 20.64% discount to the analyst consensus target price of 0.00.

Analysts covering Catalent Inc currently have a consensus Earnings Per Share (EPS) forecast of 2.805 for the next financial year.

How can I tell whether the Catalent Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Catalent Inc. Over the past six months, the relative strength of its shares against the market has been -0.2%. At the current price of $110.6, shares in Catalent Inc are trading at 13.41% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Catalent Inc PE Ratio?

The Catalent Inc PE ratio based on its reported earnings over the past 12 months is 57.35. The shares are currently trading at $110.6.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Catalent Inc?

Catalent Inc's management team is headed by:

John Chiminski - CHM
Aristippos Gennadios - CEX
Jack Stahl - LED
Rolf Classon - IND
J. Martin Carroll - IND
Steven Fasman - SVP
Wetteny Joseph - CFO
Madhavan Balachandran - IND
Alessandro Maselli - PRE
Rosemary Crane - IND
Jonathan Arnold - CEX
Ricardo Pravda - CHO
Karen Flynn - CEX
Ricci Whitlow - CEX
Charles Lickfold - SVP
Who are the major shareholders of Catalent Inc?

Here are the top five shareholders of Catalent Inc based on the size of their shareholding:

T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 11.96% (20.4m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 10.26% (17.5m shares)
Janus Henderson Investors Investment Advisor/Hedge Fund
Percentage owned: 7.02% (11.9m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.97% (8.46m shares)
T. Rowe Price Mid-Cap Growth Fund Mutual Fund
Percentage owned: 4.66% (7.94m shares)
Similar to CTLT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.